Henlius and Organon Announce U.S. FDA Approval of POHERDY®, the First Interchangeable Pertuzumab Biosimilar in the United States Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced a major regulatory milestone with the U.S. Food and Drug Administration’s (FDA)…
Sonoma Biotherapeutics Announces Leadership Transition as Stephen Dilly, MBBS, PhD, Becomes President and CEO; Co-founder Jeff Bluestone, PhD, Assumes Advisory Role Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company advancing engineered regulatory T-cell (Treg) therapies for autoimmune and inflammatory diseases, announced…
Scribe Therapeutics Highlights Major ASCVD Lipid Insights at AHA 2025 Scribe Therapeutics Inc. (“Scribe”), a leading genetic medicines company engineering next-generation in vivo CRISPR-based treatments, unveiled a series of breakthrough preclinical findings across its cardiometabolic pipeline at the 2025 American…
Inflammasome Therapeutics to Collaborate with Healey & AMG Center on New ALS Treatment Study Inflammasome Therapeutics, a clinical-stage biotechnology company advancing a new category of drug candidates known as Kamuvudines for ophthalmic and neurological diseases, announced that it has signed…
Deciphera to Present Comprehensive Pipeline Data at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and its subsidiary Deciphera Pharmaceuticals, Inc. today announced that new and…
Ionis Pharmaceuticals Announces $700 Million Convertible Senior Notes Offering to Refinance 2026 Debt and Strengthen Long-Term Financial Flexibility Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a leading biopharmaceutical company advancing RNA-targeted therapeutics, today announced that it intends to offer, subject to market…
FDA Grants Orphan Drug Designation to Tinostamustine for the Treatment of Malignant Glioma Purdue Pharma L.P. (“Purdue”) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational therapy tinostamustine for the…
Mirum Pharmaceuticals Spotlights Advancements in Rare Liver Disease With New Data From LIVMARLI® and Volixibat Programs at AASLD’s The Liver Meeting® 2025 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biotechnology company focused on developing and commercializing therapies for rare and severe…
Stoke Therapeutics Reports Third Quarter 2025 Results and Highlights Clinical and Corporate Progress Toward Transformational RNA Medicines Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering the use of RNA-based medicines designed to restore healthy protein levels, announced its financial…
QIAGEN to Acquire Parse Biosciences, Expanding Portfolio into Scalable Single-Cell Sequencing and AI-Driven Discovery QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading U.S.-based innovator in…
PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a biotherapeutics innovator renowned for its hub-and-spoke model that…
Kyowa Kirin International Appoints Julie Dehaene-Puype as President, Ushering in a New Era of Leadership and Growth Kyowa Kirin International (“KKI”), a regional group company of Kyowa Kirin Co., Ltd. (TSE: 4151), a leading Japan-based global specialty pharmaceutical company, has…